Para-aortic lymph node recurrence in surgically treated early-stage cervical cancer without para-aortic lymph node surgical staging.

Cervical Cancer Lymph Nodes Neoplasm Recurrence, Local

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
08 Oct 2024
Historique:
medline: 9 10 2024
pubmed: 9 10 2024
entrez: 8 10 2024
Statut: aheadofprint

Résumé

The standard treatment for early-stage cervical cancer includes radical hysterectomy with pelvic lymph node staging ± bilateral salpingo-oophorectomy. Para-aortic lymphadenectomy may be considered; however, its role remains controversial. The objective of this study was to assess the para-aortic lymph node recurrence rate in patients undergoing surgery for apparent early-stage cervical cancer without para-aortic lymph node surgical staging. This is a retrospective cohort study including all consecutive patients with presumed early-stage (International Federation of Gynecology and Obstetrics (FIGO) 2018 IA1-IB2, IIA1) cervical cancer who underwent radical surgery at the European Institute of Oncology, Milan, Italy. Pelvic lymph node assessment included sentinel lymph node biopsy and/or systematic pelvic lymphadenectomy. Patients who underwent para-aortic lymphadenectomy or had an indication to receive adjuvant para-aortic radiotherapy were excluded. The Kaplan-Meier method was used to estimate 5-year recurrence-free survival. Overall, 432 patients were included. The median age was 43.7 years (IQR 38.1-51.6). Sixteen (3.7%) patients were staged IA1 at diagnosis, 24 (5.6%) IA2, 208 (48.1%) IB1, 177 (41%) IB2, and 7 (1.6%) IIA1. At final pathology, the stage distribution was as follows: 36 (8.3%) stage IA1-IA2, 323 (74.8%) stage IB1-IB3, 17 (3.9%) stage II, and 56 (13%) stage IIIC1. Eighty-two patients (19%) underwent concurrent pelvic chemoradiotherapy, 20 (4.6%) radiotherapy alone, and 3 (0.7%) chemotherapy alone. Thirty-eight (8.8%) patients experienced a recurrence with a median time of 18 months (IQR 12-29). The median follow-up time for the remaining 394 (91.2%) patients was 70 months (IQR 36-98). Two patients (0.5%) had a recurrence in the para-aortic lymph nodes. The 5-year recurrence-free survival in the overall cohort was 90% (95% CI 87.4% to 93.3%). Given the low rate of para-aortic lymph node recurrence in surgically treated early-stage cervical cancer and the well-established peri-operative complications associated with para-aortic lymphadenectomy, our study aligns with recent evidence supporting the omission of this procedure in such patients.

Identifiants

pubmed: 39379329
pii: ijgc-2024-005950
doi: 10.1136/ijgc-2024-005950
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Tullio Golia D'Augè (T)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

Giuseppe Caruso (G)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
Department of Experimental Medicine, University of Rome La Sapienza, Rome, Italy.

Maria Elena Laudani (ME)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
Department of Surgical Sciences, University of Turin, Turin, Italy.

Ludovica Nazzaro (L)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

Luigi Antonio De Vitis (LA)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

Nelia Marina Rosanu (NM)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

Lucia Ribero (L)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

Sarah Alessi (S)

Division of Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

Roberta Lazzari (R)

Department of Radiotherapy, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

Ilaria Betella (I)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

Giovanni Aletti (G)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Vanna Zanagnolo (V)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

Nicoletta Colombo (N)

Gynecology Program, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.

Gabriella Schivardi (G)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy g.schivardi@gmail.com.

Francesco Multinu (F)

Department of Gynecologic Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

Classifications MeSH